Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has issued an update.
Jiangsu Hengrui Pharmaceuticals has entered into two continuing connected transactions with Hansoh Pharma and its subsidiary, aimed at expanding the development and commercialization of specific drug products in mainland China. Under a 20-year licensing agreement signed on 26 December 2025, Hengrui grants Hansoh Pharma an exclusive licence to develop, manufacture and commercialize a designated product in the PRC, in return for upfront, milestone and royalty payments; in parallel, Hengrui’s subsidiary Chengdu Suncadia has agreed a commercialization services framework with Jiangsu Hansoh, under which the latter will provide non-exclusive commercialization services for an entrusted product. Because Hansoh Pharma is controlled by the spouse of Hengrui’s chairman, both deals are classified as continuing connected transactions under Hong Kong listing rules, triggering reporting and annual review requirements but exempting them from independent shareholders’ approval, while the unusually long 20-year term of the licensing deal requires an independent financial adviser’s opinion on market practice, underscoring heightened governance scrutiny for investors and other stakeholders.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company focused on the research, development, manufacturing and commercialization of innovative medicines. Listed in Hong Kong, it operates within the domestic PRC pharmaceutical market and collaborates with industry peers to expand its product pipeline and commercial reach.
Average Trading Volume: 3,577,536
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$447.6B
For an in-depth examination of 1276 stock, go to TipRanks’ Overview page.